Drug Profile
Research programme: anti-C35 breast cancer antibodies - Vaccinex
Alternative Names: C35 antibody; VX 35; VX-C35; VX35/anti-C35 antibodyLatest Information Update: 08 Oct 2015
Price :
$50
*
At a glance
- Originator Vaccinex
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants; NF-kappa B modulators; Protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 08 Oct 2015 Discontinued - Preclinical for Breast cancer in USA (Parenteral)
- 18 Oct 2012 VX35 is still in preclinical trials for Breast cancer in USA
- 30 Jun 2004 Preclinical trials in Cancer in USA (unspecified route)